Effects of calcifediol supplementation on markers of chronic kidney disease-mineral and bone disorder in dogs with chronic kidney disease.
25-hydroxyvitamin D
calcitriol
fibroblast growth factor-23
fractional excretion
parathyroid hormone
urine calcium-to-creatinine ratio
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
31
03
2020
revised:
11
10
2020
accepted:
19
10
2020
pubmed:
1
11
2020
medline:
29
6
2021
entrez:
31
10
2020
Statut:
ppublish
Résumé
Chronic kidney disease-mineral and bone disorder (CKD-MBD) in dogs is associated with hypovitaminosis D, increased parathyroid hormone (PTH), and increased fibroblast growth factor-23 (FGF-23) concentrations. Best practice for vitamin D metabolite supplementation in CKD-MBD remains unknown. To provide an extended-release calcifediol supplement to dogs with CKD and to measure its effects on variables indicative of CKD-MBD. Ten dogs with International Renal Interest Society stages 2 and 3 CKD. In a prospective study, dogs received a calcifediol supplement for 84 days. Serum 25-hydroxyvitamin D (25[OH]D), 1,25-dihydroxyvitamin D (1,25[OH] All serum vitamin D metabolite concentrations increased significantly by day 84 (P < .001): [25(OH)D (median 249.9 ng/mL; range, 149.7-469.9 ng/mL) compared to baseline (median 50.2 ng/mL; range, 31.3-66.0 ng/mL); 1,25(OH) Calcifediol supplementation for 84 days was well-tolerated in dogs with IRIS stages 2 and 3 CKD. It remains to be determined how long-term supplementation would affect CKD progression and QOL.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic kidney disease-mineral and bone disorder (CKD-MBD) in dogs is associated with hypovitaminosis D, increased parathyroid hormone (PTH), and increased fibroblast growth factor-23 (FGF-23) concentrations. Best practice for vitamin D metabolite supplementation in CKD-MBD remains unknown.
OBJECTIVE
OBJECTIVE
To provide an extended-release calcifediol supplement to dogs with CKD and to measure its effects on variables indicative of CKD-MBD.
ANIMALS
METHODS
Ten dogs with International Renal Interest Society stages 2 and 3 CKD.
METHODS
METHODS
In a prospective study, dogs received a calcifediol supplement for 84 days. Serum 25-hydroxyvitamin D (25[OH]D), 1,25-dihydroxyvitamin D (1,25[OH]
RESULTS
RESULTS
All serum vitamin D metabolite concentrations increased significantly by day 84 (P < .001): [25(OH)D (median 249.9 ng/mL; range, 149.7-469.9 ng/mL) compared to baseline (median 50.2 ng/mL; range, 31.3-66.0 ng/mL); 1,25(OH)
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
Calcifediol supplementation for 84 days was well-tolerated in dogs with IRIS stages 2 and 3 CKD. It remains to be determined how long-term supplementation would affect CKD progression and QOL.
Identifiants
pubmed: 33128421
doi: 10.1111/jvim.15949
pmc: PMC7694821
doi:
Substances chimiques
Parathyroid Hormone
0
Vitamin D
1406-16-2
Calcifediol
P6YZ13C99Q
Calcium
SY7Q814VUP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2497-2506Subventions
Organisme : EirGen Pharma/OPKO Health, Inc
Organisme : NCATS NIH HHS
ID : UL1TR002733
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1TR002733
Pays : United States
Informations de copyright
© 2020 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Références
Turk J Pediatr. 2012 Mar-Apr;54(2):93-8
pubmed: 22734293
Vet Clin North Am Small Anim Pract. 2016 Nov;46(6):1131-49
pubmed: 27436330
J Vet Intern Med. 2016 Jan-Feb;30(1):183-91
pubmed: 26567089
J Vet Intern Med. 2017 May;31(3):784-790
pubmed: 28419560
Am J Vet Res. 1992 Mar;53(3):326-34
pubmed: 1595957
Am J Vet Res. 2005 Aug;66(8):1330-6
pubmed: 16173474
J Nutr Sci. 2016 Jul 29;5:e31
pubmed: 27547394
J Nutr. 2020 Mar 1;150(3):427-433
pubmed: 31665381
Am J Vet Res. 1991 May;52(5):718-22
pubmed: 1854095
J Vet Intern Med. 2017 May;31(3):791-798
pubmed: 28186657
J Am Vet Med Assoc. 1999 May 1;214(9):1336-41
pubmed: 10319174
J Nutr Sci. 2017 Jun 20;6:e30
pubmed: 29152235
JAMA. 2011 Jun 15;305(23):2432-9
pubmed: 21673295
Prev Vet Med. 2010 May 1;94(3-4):264-71
pubmed: 20129684
J Vet Intern Med. 2015 Jan;29(1):113-9
pubmed: 25581880
Kidney Int. 2009 Jan;75(1):88-95
pubmed: 18843258
Clin J Am Soc Nephrol. 2009 Sep;4(9):1529-39
pubmed: 19661219
Nephrol Dial Transplant. 2009 Sep;24(9):2792-6
pubmed: 19395730
BMC Res Notes. 2015 Sep 15;8:442
pubmed: 26374201
J Vet Intern Med. 2020 Nov;34(6):2497-2506
pubmed: 33128421
Int J Nephrol Renovasc Dis. 2019 Dec 24;12:263-276
pubmed: 31920363
Ann Clin Biochem. 2006 Sep;43(Pt 5):398-401
pubmed: 17022882
Vet Rec. 2018 Apr 7;182(14):406
pubmed: 29419484
J Steroid Biochem Mol Biol. 2015 Apr;148:283-9
pubmed: 25446887
J Vet Intern Med. 2018 Nov;32(6):1977-1982
pubmed: 30325060
J Am Vet Med Assoc. 2014 Nov 15;245(10):1135-40
pubmed: 25356714
Vet Comp Oncol. 2016 Sep;14(3):295-305
pubmed: 25041357
Expert Opin Pharmacother. 2019 Dec;20(17):2081-2093
pubmed: 31675257
Aust Vet J. 2006 Nov;84(11):393-7
pubmed: 17092324
J Ren Nutr. 2019 Jan;29(1):2-15
pubmed: 30150095
Nutrients. 2017 Mar 25;9(4):
pubmed: 28346348
J Vet Intern Med. 2010 Jan-Feb;24(1):73-9
pubmed: 19925576
Vet Clin Pathol. 2008 Mar;37(1):4-20
pubmed: 18366540
Nutrients. 2018 Dec 03;10(12):
pubmed: 30513912
J Nutr Biochem. 2017 Aug;46:21-29
pubmed: 28437713
Am J Clin Nutr. 2008 Aug;88(2):582S-586S
pubmed: 18689406
Am J Nephrol. 2016;44(4):316-325
pubmed: 27676085
Vet Comp Oncol. 2011 Sep;9(3):172-82
pubmed: 21848620